Waters Corporation Presents Financial Outlook and Proposed Transaction at J.P. Morgan Healthcare Conference

Details

Morgan 44th Annual Healthcare Conference on January 12, 2026. The presentation included high-level commentary on the Company's business performance, future financial outlook, and a proposed transaction with Augusta SpinCo Corporation and Becton, Dickinson and Company. The presentation highlighted Waters' strong financial profile, industry-leading growth, and significant value creation opportunity from the proposed transaction. Key financial metrics, such as organic constant-currency revenue growth, free cash flow, and adjusted operating margin, were provided. The proposed transaction aims to accelerate high-growth adjacencies, achieve cost and revenue synergies, and expand Waters' Total Addressable Market to $40B in attractive, growth-accretive markets.

Items reported

About Waters Corporation

Waters Corporation is a leading entity in the field of analytical instruments and software. It primarily focuses on providing laboratory solutions for a variety of sectors, including pharmaceuticals, healthcare, food and beverage, and chemical analysis. The company's offerings include high-performance liquid chromatography, mass spectrometry systems, and various supporting technologies used for advanced research in life sciences. Waters Corporation is pivotal in enhancing laboratory productivity, offering cutting-edge research tools that assist in drug development, quality control, and environmental testing. Operating globally, it serves a wide array of clients, including academic institutions, government agencies, and private industry players. With its commitment to innovation and precision, Waters Corporation plays a crucial role in advancing scientific and technological progress in multiple critical industries worldwide.